Sponsored

Biomarker Testing and Targeted Therapy in NSCLC: Review and Update

November 14th 2023

Expert Derek Lyle, MD, provides an in-depth overview of biomarker testing and targeted therapy in the current landscape of non–small cell lung cancer management.

Responding to Resistance in Lung Cancer

October 25th 2023

Non-Hodgkin’s Lymphoma: New Medicines that Address Patient Needs

August 14th 2023

Krish Patel, MD, discusses the latest advances in the treatment of non-Hodgkin’s lymphoma and how fixed-duration treatment options can improve the overall patient experience.

An Individualized Approach to Treating Advanced RCC

July 31st 2023

Grounded in a collaborative and personalized approach, researcher and clinician Dr. Thomas Hutson expands on his best practices for treating certain people living with advanced RCC with a combination therapy.

Recognizing Appropriate Patients for an Antibody-Drug Conjugate: Case Studies in Bladder Cancer

July 24th 2023

Bispecific Targeting CD3 and BCMA Reflect Expanding Options in Multiple Myeloma

July 12th 2023

Bispecific antibodies targeting BCMA have shown efficacy in relapsed refractory multiple myeloma, including bispecifics targeting BCMA x CD3.

Extending Overall Survival in Patients with Advanced Urothelial Carcinoma

July 3rd 2023

The Evolving Advanced RCC Treatment Landscape

June 26th 2023

Researcher and clinician, Dr. Thomas Hutson reflects on the modern patient journey and shares his experience treating people with advanced RCC. Through the years, the advanced RCC treatment landscape has evolved significantly. In this two-part series brought to you by Eisai Inc., hear from oncologist Thomas Hutson, DO as he reflects on best practices for evaluating today’s treatment options.

Health Equity Isn't a Theme, It's a Long-term Commitment

May 30th 2023

Important Considerations for Biomarker Testing in NSCLC at Key Points in Treatment Journey

May 26th 2023

The biomarker testing landscape has evolved over the years, affecting how oncologists approach lung cancer.

Bringing Precision Medicine to Community Oncology is Going to Require Bigger Thinking

May 23rd 2023

Extended Follow-up Analysis of First-Line Treatment for Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma

April 28th 2023

Live Broadcast: Explore the Efficacy and Safety Data for a Treatment Option for Certain Patients With ESR1-Mutated ER+/HER2- mBC

April 6th 2023

Live Broadcast to Explore a Newly Approved Treatment Option Available for Patients With Pretreated HR+/HER2-negative Metastatic Breast Cancer

February 28th 2023

ASH: Preliminary Clinical Data for TP-3654 in Myelofibrosis

January 30th 2023

FDA-Approved Adjuvant Treatment for Patients with High-Risk Urothelial Carcinoma

December 21st 2022

Improving outcomes in metastatic pancreatic cancer

November 30th 2022

Pancreatic cancer remains elusive with extremely low survival rates. Through better utilization of existing therapies and identifying patient subgroups, some believe we are incrementally improving patient outcomes and making more significant advances in care.

Pursuing Additional Options for Patients With Chronic Lymphocytic Leukemia

October 3rd 2022

Sponsored content by AbbVie

Rethinking I-O in PROC: A Potential Answer in Two vs. One

July 20th 2022

Challenges in the Management of MDS

March 2nd 2022